3mxd
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | [[ | + | ==Crystal structure of HIV-1 protease inhibitor KC53 in complex with wild-type protease== |
+ | <StructureSection load='3mxd' size='340' side='right' caption='[[3mxd]], [[Resolution|resolution]] 1.95Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[3mxd]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Hiv-1_m:b_arv2/sf2 Hiv-1 m:b_arv2/sf2]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3MXD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3MXD FirstGlance]. <br> | ||
+ | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=K53:(5S)-N-{(1S,2R)-3-[(1,3-BENZODIOXOL-5-YLSULFONYL)(2-METHYLPROPYL)AMINO]-1-BENZYL-2-HYDROXYPROPYL}-3-(2-HYDROXYPHENYL)-2-OXO-1,3-OXAZOLIDINE-5-CARBOXAMIDE'>K53</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr> | ||
+ | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3mxe|3mxe]]</td></tr> | ||
+ | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">gag-pol ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=11685 HIV-1 M:B_ARV2/SF2])</td></tr> | ||
+ | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] </span></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3mxd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3mxd OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3mxd RCSB], [http://www.ebi.ac.uk/pdbsum/3mxd PDBsum]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | A series of new HIV-1 protease inhibitors with the hydroxyethylamine core and different phenyloxazolidinone P2 ligands were designed and synthesized. Variation of phenyl substitutions at the P2 and P2' moieties significantly affected the binding affinity and antiviral potency of the inhibitors. In general, compounds with 2- and 4-substituted phenyloxazolidinones at P2 exhibited lower binding affinities than 3-substituted analogues. Crystal structure analyses of ligand-enzyme complexes revealed different binding modes for 2- and 3-substituted P2 moieties in the protease S2 binding pocket, which may explain their different binding affinities. Several compounds with 3-substituted P2 moieties demonstrated picomolar binding affinity and low nanomolar antiviral potency against patient-derived viruses from HIV-1 clades A, B, and C, and most retained potency against drug-resistant viruses. Further optimization of these compounds using structure-based design may lead to the development of novel protease inhibitors with improved activity against drug-resistant strains of HIV-1. | ||
- | + | Structure-Based Design, Synthesis, and Structure-Activity Relationship Studies of HIV-1 Protease Inhibitors Incorporating Phenyloxazolidinones.,Ali A, Reddy GS, Nalam MN, Anjum SG, Cao H, Schiffer CA, Rana TM J Med Chem. 2010 Nov 11;53(21):7699-708. PMID:20958050<ref>PMID:20958050</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
==See Also== | ==See Also== | ||
*[[Virus protease|Virus protease]] | *[[Virus protease|Virus protease]] | ||
- | + | == References == | |
- | == | + | <references/> |
- | < | + | __TOC__ |
+ | </StructureSection> | ||
[[Category: HIV-1 retropepsin]] | [[Category: HIV-1 retropepsin]] | ||
[[Category: Hiv-1 m:b_arv2/sf2]] | [[Category: Hiv-1 m:b_arv2/sf2]] | ||
- | [[Category: Nalam, M N.L | + | [[Category: Nalam, M N.L]] |
- | [[Category: Schiffer, C A | + | [[Category: Schiffer, C A]] |
[[Category: Drug design]] | [[Category: Drug design]] | ||
[[Category: Hiv-1 protease]] | [[Category: Hiv-1 protease]] | ||
[[Category: Hydrolase-hydrolase inhibitor complex]] | [[Category: Hydrolase-hydrolase inhibitor complex]] | ||
[[Category: Protease inhibitor]] | [[Category: Protease inhibitor]] |
Revision as of 08:32, 9 December 2014
Crystal structure of HIV-1 protease inhibitor KC53 in complex with wild-type protease
|